Novel avenues of tau research

Claire E Sexton¹, Gal Bitan², Kathryn R Bowles³, Miroslaw Brys⁴, Luc Buée⁵, Mahmoud Bukar Maina^{6

7}, Claire D Clelland⁸, Ann D Cohen⁹, John F Crary¹⁰, Jeffrey L Dage¹¹, Kristophe Diaz¹², Bess Frost¹³, Li Gan¹⁴, Alison M Goate¹⁵, Lawrence I Golbe^{12

16}, Oskar Hansson¹⁷, Celeste M Karch¹⁸, Hartmuth C Kolb¹⁹, Renaud La Joie⁸, Suzee E Lee⁸, Diana Matallana^{20

21}, Bruce L Miller^{8

22}, Chiadi U Onyike²³, Yakeel T Quiroz²⁴, Jessica E Rexach²⁵, Jonathan D Rohrer²⁶, Amy Rommel²⁷, Ghazaleh Sadri-Vakili²⁸, Suzanne E Schindler²⁹, Julie A Schneider³⁰, Reisa A Sperling³¹, Charlotte E Teunissen³², Stacie C Weninger³³, Susan L Worley³⁴, Hui Zheng³⁵, Maria C Carrillo¹

Affiliations

¹ Alzheimer's Association, Chicago, Illinois, USA.
² Department of Neurology, David Geffen School of Medicine, Brain Research Institute, Molecular Biology Institute, University of California Los Angeles (UCLA), Los Angeles, California, USA.
³ UK Dementia Research Institute at the University of Edinburgh, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
⁴ Eli Lilly & Co., Indianapolis, Indiana, USA.
⁵ Univ Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, LabEx DISTALZ, Place de Verdun, Lille, France.
⁶ Sussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, UK.
⁷ Biomedical Science Research and Training Centre, Yobe State University, Damaturu, Nigeria.
⁸ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
⁹ University of Pittsburgh, School of Medicine, Department of Psychiatry and Alzheimer's disease Research Center, Pittsburgh, Pennsylvania, USA.
¹⁰ Departments of Pathology, Neuroscience, and Artificial Intelligence & Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹¹ Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹² CurePSP, Inc, New York, New York, USA.
¹³ Sam & Ann Barshop Institute for Longevity & Aging Studies Glenn Biggs Institute for Alzheimer's & Neurodegenerative Disorders Department of Cell Systems and Anatomy University of Texas Health San Antonio, San Antonio, Texas, USA.
¹⁴ Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.
¹⁵ Department of Genetics & Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁶ Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
¹⁷ Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
¹⁸ Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
¹⁹ Janssen R&D, Neuroscience, San Diego, California, USA.
²⁰ Aging Institute, Neuroscience Program, Psychiatry Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
²¹ Mental Health Department, Hospital Universitario Fundaciòn Santa Fe, Bogota, Colombia.
²² Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
²³ Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, Baltimore, Maryland, USA.
²⁴ Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
²⁵ Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
²⁶ Department of Neurodegenerative Disease, Dementia Research Centre, University College London Institute of Neurology, Queen Square, London, UK.
²⁷ Rainwater Charitable Foundation, Fort Worth, Texas, USA.
²⁸ Sean M. Healey &AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.
²⁹ Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
³⁰ Rush Alzheimer's Disease Center, Chicago, Illinois, USA.
³¹ Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³² Neurochemistry Laboratory, Clinical Chemistry department, Amsterdam Neuroscience, Program Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
³³ FBRI, Cambridge, Massachusetts, USA.
³⁴ Independent Science Writer, Bryn Mawr, Pennsylvania, USA.
³⁵ Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.

PMID: 38170841
PMCID: PMC10984447
DOI: 10.1002/alz.13533

Review

Novel avenues of tau research

Claire E Sexton et al. Alzheimers Dement. 2024 Mar.

. 2024 Mar;20(3):2240-2261.

doi: 10.1002/alz.13533. Epub 2024 Jan 3.

Authors

Affiliations

¹ Alzheimer's Association, Chicago, Illinois, USA.
² Department of Neurology, David Geffen School of Medicine, Brain Research Institute, Molecular Biology Institute, University of California Los Angeles (UCLA), Los Angeles, California, USA.
³ UK Dementia Research Institute at the University of Edinburgh, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
⁴ Eli Lilly & Co., Indianapolis, Indiana, USA.
⁵ Univ Lille, Inserm, CHU-Lille, Lille Neuroscience and Cognition, LabEx DISTALZ, Place de Verdun, Lille, France.
⁶ Sussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, UK.
⁷ Biomedical Science Research and Training Centre, Yobe State University, Damaturu, Nigeria.
⁸ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
⁹ University of Pittsburgh, School of Medicine, Department of Psychiatry and Alzheimer's disease Research Center, Pittsburgh, Pennsylvania, USA.
¹⁰ Departments of Pathology, Neuroscience, and Artificial Intelligence & Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹¹ Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹² CurePSP, Inc, New York, New York, USA.
¹³ Sam & Ann Barshop Institute for Longevity & Aging Studies Glenn Biggs Institute for Alzheimer's & Neurodegenerative Disorders Department of Cell Systems and Anatomy University of Texas Health San Antonio, San Antonio, Texas, USA.
¹⁴ Helen and Robert Appel Alzheimer Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.
¹⁵ Department of Genetics & Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁶ Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
¹⁷ Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
¹⁸ Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
¹⁹ Janssen R&D, Neuroscience, San Diego, California, USA.
²⁰ Aging Institute, Neuroscience Program, Psychiatry Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
²¹ Mental Health Department, Hospital Universitario Fundaciòn Santa Fe, Bogota, Colombia.
²² Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
²³ Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, Baltimore, Maryland, USA.
²⁴ Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
²⁵ Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
²⁶ Department of Neurodegenerative Disease, Dementia Research Centre, University College London Institute of Neurology, Queen Square, London, UK.
²⁷ Rainwater Charitable Foundation, Fort Worth, Texas, USA.
²⁸ Sean M. Healey &AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.
²⁹ Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
³⁰ Rush Alzheimer's Disease Center, Chicago, Illinois, USA.
³¹ Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³² Neurochemistry Laboratory, Clinical Chemistry department, Amsterdam Neuroscience, Program Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
³³ FBRI, Cambridge, Massachusetts, USA.
³⁴ Independent Science Writer, Bryn Mawr, Pennsylvania, USA.
³⁵ Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.

PMID: 38170841
PMCID: PMC10984447
DOI: 10.1002/alz.13533

Abstract

Introduction: The pace of innovation has accelerated in virtually every area of tau research in just the past few years.

Methods: In February 2022, leading international tau experts convened to share selected highlights of this work during Tau 2022, the second international tau conference co-organized and co-sponsored by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation.

Results: Representing academia, industry, and the philanthropic sector, presenters joined more than 1700 registered attendees from 59 countries, spanning six continents, to share recent advances and exciting new directions in tau research.

Discussion: The virtual meeting provided an opportunity to foster cross-sector collaboration and partnerships as well as a forum for updating colleagues on research-advancing tools and programs that are steadily moving the field forward.

Keywords: biomarkers; tau; tau-PET; tauopathies; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Claire Sexton has nothing to disclose. G. Bitan has nothing to disclose. K. R. Bowles has nothing to disclose. M. Brys reports patents planned, issued, or pending; stock or stock options; other financial or non‐financial interests from Eli Lilly & Co. L. Buée reports grants or contracts from T‐PEP AA and RCF, USA; ANR, France; consulting fees: Aptah Bio, USA; Beckman Coulter, USA; support for attending meetings: ADPD, AAIC; patents: EP22306999.8 Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy, December 2022; EP 21306903.2 Methods for improving the efficacy of HDAC inhibitor therapy and predicting the response to treatment with HDAC inhibitor, December 2021. M. Bukar – Maina reports grants or contracts from the Alzheimer's Association Research Fellowship; University of Sussex; support for attending meetings: Alzheimer's Research UK South Coast Network, University of Sussex Neuroscience, Alzheimer's Association Research Fellowship; leadership or fiduciary role: Society of Neuroscientists of Africa, Yobe State Government, TReND in Africa. L. B. serves on the Wellcome Trust LMIC Advisory Board. C. D. Clelland reports grants or contracts from BrightFocus Foundation Fellowship, Alzheimer's Association Clinician Scientist Fellowship, NIH/NINDS K08‐NS112330KO8, Carol and Gene Ludwig Award for Early Career Research, Larry H. Hillblom Fellowship, Wolfen Family Foundation, and Wozniak Family gifts. A. D. Cohen reports grants or contracts: R01 AG052446, R01 AG072641, P30 AG066468, P01 AG025204‐16, U19 AG068054, R01 AG063525, R37 AG023651, RF1 AG025516, RF1 AG052525, U19 AG024904‐01, AG078109‐01, P50 MH130957‐01, R01 AG075992‐01, U01 NS100610‐06; receipt of AV1451 precursor from Avid. J. F. Crary reports grants or contracts: NIH grants R01AG054008, R01NS095252, RF1AG060961, R01NS086736, R01AG062348, RF1MH128969, P30AG066514, R01AG063819, R01NS116006, U54NS115266; support for attending meetings: Rainwater Charitable Foundation/Tau Consortium. J. L. Dage reports grants or contracts: NIH/NIA institution, Roche institution, Clinical and Translational Science Institute; consulting fees: Genotix Biotechnologies Inc., Gates Ventures, Karuna Therapeutics, AlzPath Inc., Cognito, AbbVie, Eisai; payment or honoraria: Eli Lilly and Company; patents: patents filed relating to assays, methods, reagents, and/or compositions of matter used in this work – assigned to Eli Lilly and Co.; leadership or fiduciary role: ADC Biomarker Steering Committee; Vice Chair ISTAART BBB PIA; stock or stock options: Eli Lilly and Co. minor shareholder, AlzPath, Monument Biosciences, Genotix Biotechnologies Inc.; receipt of equipment, materials, drugs, medical writing, gifts, or other services: Roche Diagnostics, ADx Neurosciences, Eli Lilly and Co. K. Diaz has nothing to disclose. B. Frost reports grants or contracts: 1 R01 AG078964, 1 R01 AG058778‐01, 1 RF1 NS112391‐01, 1 R01 AG074289, 1 R01 AG062475‐01A1, UTHSCSA Pepper Center, Center for Biomedical Neurosciences Pilot Grant, William and Ella Owens Medical Research Foundation, Transposon Therapeutics, Rainwater Foundation/Tau Consortium, MD Anderson Neurodegeneration Consortium; consulting fees: MD Anderson Neurodegeneration Consortium; paid travel: 2023, Tau Consortium and 2022, Tau Consortium from Rainwater Foundation; 2023, Neurodegeneration Consortium, 2022, Neurodegeneration Consortium from MD Anderson; 2023, Glenn Workshop from AFAR. Leadership or fiduciary role: co‐organizer, Tau 2024 Conference; associate editor, Progress in Neurobiology. L. Gan reports grants or contracts: NIA/NIH: R01AG072758, NIA/NIH: R01AG074541, NIA/NIH: 1R01AG077899, Rainwater Foundation; JPB Foundation all funding to Weill Cornell. Consulting fees: Ono Pharma USA; honoraria: 17th Wisconsin Stem Cell Symposium; 8th Annual Neuroimmunology and Glia Group (NGG) retreat; Mayo Clinic Department of Neuroscience Virtual Seminar; University of Pittsburg, Aging Research Seminar Series; University of Arizona School of Pharmacy. Travel and accommodation support: DZNE Lecture Series in Bonn, Bonn, Germany; DZNE/Synergy seminar series, Munich, Germany; GRC on Neurobiology of Brain Disorders: Understanding disease mechanisms and developing novel therapeutics for neurodegeneration, Castelldefels, Spain; Cold Spring Harbor Meeting: Neurodegenerative Diseases and Biology; AD/PD 2023, Presymposium; Keystone Symposia on Neuroimmune Interactions and Neurodegeneration; Alzheimer's Association International Conference; GRC Neuroimmune Communication in Health and Disease; 8th Annual Neuroimmunology and Glia Group (NGG) retreat; Spring Brain Conference; BIG Symposium, Washington University in St. Louis, School of Medicine; FBRI Workshop on Alzheimer's Disease. Patents: US patent application: “cGas Inhibitors and Uses Thereof” 63/309,894 ‐ one of the inventors. Equity holder: Aeton Therapeutics. A.M. Goate reports grants or contracts: JPB Foundation; Rainwater Charitable Foundation; Cure Alzheimer's fund paid to institution. Royalties or licenses: Taconic Industries, Athena Diagnostics; consulting fees: Genentech, Muna Therapeutics. Payment or honoraria: Biogen, Genentech. Support for attending meetings: Rainwater Charitable Foundation; patents: 6,475,723 Pathogenic tau mutations – Licensed to Taconic Industries; 5,973,133 Mutant S182 genes; 5,877,015 APP770 mutant in AD. Stock or stock options: Cognition Therapeutics, Denali Therapeutics. L. I. Golbe reports royalties or licenses: Rutgers University (PSP Rating Scale, video guide to the PSP rating scale), Rutgers University Press (A Clinician's Guide to Progressive Supranuclear Palsy [2019]). Consulting fees: AI Therapeutics, Amylyx, Aprinoia, Ferrer (Asceneuron), Mitochon, Switch, UCB. Travel support from CurePSP as Chief Clinical Officer and board of directors member. Participation on DSMB or AB for Rossy Centre, University of Toronto; leadership or fiduciary role: CurePSP: Chair, Scientific Advisory Board; Chief Clinical Officer; member, board of directors; member, Executive Committee; President, Dwight Morrow High School Alumni Educational Alliance (Englewood, NJ). O. Hansson reports consulting fees: AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, Siemens. Participation on DSMB or AB for: AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, Siemens. C. M. Karch reports grants or contracts: NIH, Rainwater Charitable Organization. H. C. Kolb report patents: inventor on patent pending for Janssen plasma p217+tau assay; stock from Johnson & Johnson, parent company of Janssen R&D. H. C. Kolb is an employee of Janssen R&D, receiving salary from said institution. R. La Joie reports grants or contracts: Alzheimer's Association, NIH/NIA, US Department of Defense. Support for attending meetings from Alzheimer's Association. S. E. Lee reports grants or contracts: NIH‐NIA, Bluefield Project; royalties or licenses: UptoDate; support for attending meetings: Tau Consortium. D. Matallana reports grants or contracts: NIH and Fogarty International Center (FIC) under Award R01AG057234, an Alzheimer's Association grant (SG‐20‐725707‐ReDLat); support for attending meetings: NIH and FIC under Award R01AG057234. B. L. Miller reports grants or contracts: NIH/Univ. of Wisconsin, Madison 1R01AG070883, NIH/NIA: R35AG072362, P01 AG019724, P30AG062422, R01AG057234, R01AG062562, R01AG062588, Bluefield Project to Cure FTD, UCSF FTD Core P0544014, NIH/NINDS R01 NS050915, NIH CSR R01AG052496. Royalties or licenses: Cambridge University Press, Elsevier, Inc., Guilford Publications, Inc., Johns Hopkins Press, Oxford University Press, Taylor & Francis Group, all payments made to him. Payment or honoraria: Global Summit on Neurodegenerative Diseases, Korean Dementia Society, Massachusetts General Hospital, dementia course, National MS Society, Don Paty Lectureship, Ochsner Neuroscience Institute, Providence Saint Joseph Medical Center, Taipei Medical University, Dementia Center, UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), University of California, Los Angeles (UCLA) Grand Rounds, University of Texas Center for Brain Health, all payments made to him. Support for attending meetings: Association for Frontotemporal Degeneration (AFTD) Education Symposium, Milken Institute FTD Scientific Retreat, California Institute of the Arts. Participation on a DSMB or advisory board: Arizona Alzheimer's Consortium, Association for Frontotemporal Degeneration, Buck Institute for Research on Aging, Cure ALS, The John Douglas French Alzheimer's Foundation, Fundación Centro de Investigación Enfermedades Neurológicas, Genworth, The Larry L. Hillblom Foundation, Massachusetts General Hospital ADRC, National Institute for Health Research Cambridge Biomedical Research Center and its subunit, the Biomedical Research Unit in Dementia, Stanford University ADRC, University of Southern California P01 Urban Air Pollution and Alzheimer's Disease: Risk, Heterogeneity, and Mechanisms, University of Washington ADRC. Leadership or fiduciary role: Bluefield Project to Cure FTD, Global Brain Health Institute, Institute for Neurodegenerative Diseases, Tau Consortium of the Rainwater Charitable Foundation. C. U. Onyike reports grants or contracts: Alector, Inc., Transposon Therapeutics, Denali Therapeutics; consulting fees: Acadia Pharmaceuticals, Reata Pharmaceuticals, Otsuka Pharmaceutical. Honoraria for lecture: Philadelphia Psychiatric Society, American Academy of Neurology Institute. Leadership or fiduciary role: AFTD Medical Advisory Council, FTD Disorders Scientific Advisory Board, Tau Consortium Scientific Advisory Board, ISFTD Executive Committee, ISTAART FTD PIA Executive Committee. Receipt of drug and materials for clinical trial: Alector Inc., Transposon Therapeutics, Denali Therapeutics. Y. T. Quiroz reports grants or contracts: Alzheimer's Association, Massachusetts General Hospital ECOR, National Institute on Aging; consulting fees from Biogen. J. E. Rexach has nothing to disclose. J. D. Rohrer reports participation on a DSMB or advisory board: Aviado Bio, Arkuda Therapeutics, Prevail Therapeutics, Denali, Wave Life Sciences. A. Rommel reports a mixed stock funds portfolio in retirement accounts – example: Vanguard, Morgan Stanley, technology funds. G. Sadri‐Vakili has nothing to disclose. S. E. Schindler reports grants or contracts: Barnes‐Jewish Hospital Foundation, National Institute on Aging Grant R01AG070941 – funding paid to institution for research. Consulting fees: Eisai; payment or honoraria: University of Wisconsin, St. Luke's Hospital, Houston Methodist Medical Center, University of Washington, University of Indiana. Support for attending meetings: National Institute on Aging Grant R01AG070941. Leadership or fiduciary role: Greater Missouri Alzheimer's Association. Plasma Ab42/Ab40 data was provided to Washington University by C2N Diagnostics at no cost. J. A. Schneider reports receipt of consulting fee from Cerveau Inc. R. A. Sperling reports consulting fees from AC Immune, Acumen, Alnylam, Cytox, Genentech, Janssen, JOMDD, Nervgen, Neuraly, Neurocentria, Oligomerix, Prothena, Renew, Shionogi, Vigil Neuroscience, Ionis, Vaxxinity all paid directly. C. E. Teunissen's research on CET is supported by the European Commission (Marie Curie International Training Network, Grant Agreement 860197 [MIRIADE]), Innovative Medicines Initiatives 3TR (Horizon 2020, Grant 831434), EPND (IMI 2 Joint Undertaking [JU], Grant 101034344) and JPND (bPRIDE), National MS Society (Progressive MS Alliance), Alzheimer's Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer's Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. CT is a recipient of ABOARD, which is a public–private partnership (PPP) receiving funding from ZonMW (No. 73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP allowance, No. LSHM20106). C. E. Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC‐Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, Vivoryon. C. E. Teunissen received payment or honoraria from Roche, Novo Nordisk, Grifols, all paid to her institution. C. E. Teunissen serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation. S. C. Weninger reports consulting fees from Denali Therapeutics. SCW is a member of the board of directors of Neumora Therapeutics, Atalanga Therapeutics, Sironax, Aratome, Eikinizo, TargetALS; Chair, board of directors, and CEO of Rugen Therapeutics, holds stock or stock options of Denali Therapeutics, Atalanta Therapeutics, Neumora Therapeutics, Rugen Therapeutics. S. L. Worley reports consulting fees, payment, or honoraria and support for attending meetings from the Alzheimer's Association. H. Zheng has nothing to disclose. M. Carrillo reports, in the past 36 months, participating on a data safety monitoring board or advisory board for US POINTER and holding a role for EASTERSEALS. Author disclosures are available in the Supporting Information.

References

1. Sexton C, Snyder H, Beher D, et al. Current directions in tau research: highlights from Tau 2020. Alzheimers Dement. 2022;18:988‐1007. doi:10.1002/alz.12452 - DOI - PubMed
1. Jadhav S, Avila J, Schöll M, et al. A walk through tau therapeutic strategies. Acta Neuropathol Commun. 2019;7:22. doi:10.1186/s40478-019-0664-z - DOI - PMC - PubMed
1. Chang CW, Shao E. Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science. 2021;371:eabb8255. doi:10.1126/science.abb8255 - DOI - PMC - PubMed
1. Liu L, Drouet V, Wu JW, et al. Trans‐synaptic spread of tau pathology in vivo. PloS One. 2012;7:e31302. doi:10.1371/journal.pone.0031302 - DOI - PMC - PubMed
1. Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid‐beta production. Neurobiol Aging. 2015;36:693‐709. doi:10.1016/j.neurobiolaging.2014.09.007 - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Novel avenues of tau research

Affiliations

Novel avenues of tau research

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous